US-based nuclear receptor research company INDIGO Biosciences has entered into an agreement with French CRO and bioreagent supplier Bertin Pharma to distribute its Nuclear Receptor Assay kits in Europe.
Designed to assist researchers during discovery and toxicology, the assay kits are used to profile compounds in research areas such as metabolic disorders, cardiovascular disease and endocrinology.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Bertin Pharma bioreagent department manager Patrick Vitaux said: “It has been a real honour to be introduced to Fred and his company and we rapidly found a lot of complementarity in our business.
“The Nuclear Assay range perfectly fit with our customer’s needs, and will empower our commercial activity.”
Indigo’s Nuclear Receptor Assay kits are designed as an all-inclusive, cell-based, robust, and ready to use product which can screen small numbers of test compounds as well as high throughput screening (HTS) application.
The test compounds can be scanned for agonist or antagonist activities against human nuclear receptors exhibited within the cytoplasm and nuclear environments of healthy mammalian cells.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe assay kits are based on fire fly luciferase reporter gene technology which facilitates optimal assay sensitivity and dynamic range when quantifying nuclear receptor activity.
After ligand-activation, the nuclear receptor complex induces expression of the luciferase reporter.
The detection reagent after being added, the intensity of light emission from the luciferase reaction directly correlates to the activation status of the nuclear receptor.
Image: A Nuclear Receptor Assay kit. Photo: courtesy of INDIGO Biosciences.
